Robert M. Rifkin, MD

Robert M. Rifkin, MD, FACP, discusses the use of prophylactic tocilizumab to reduce teclistamab-related CRS in relapsed/refractory myeloma.

Robert M. Rifkin, MD, FACP, discusses corneal toxicities with belantamab mafodotin-blmf in multiple myeloma.

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.